Gastroenterology and Hepatology from Bed to Bench,
Background: miR-125 family (including miR-125a, miR-125b) have been reported as pivotal prognostic biomarkers of gastric cancer (GC). However, there is controversy about the role of miR-125 family in progression prediction of GC.
Aim: We design this meta-analysis to reassess the prognostic and clinicopathologic values of microRNA-125 family in GC patients.
Methods: Studies were systemically searched from electronic databases of PubMed, ISI Web of Science, Scopus and Cochrane library. The overall hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) was calculated to evaluate the association between miR-125 family expression with prognosis and susceptibility to gastric cancer. The quality of evidence was evaluated using Newcastle-Ottava Scale (NOS).
Results: Totally 1203 GC patients in ten studies were analyzed in this meta-analysis. The results showed a high significant association between the ratio of low/high expression of miR-125a (HR= 1.7; 95% CI: 1.38 to 2.08; P< 0.001) and poor OS in patients with GC, while, this ratio for miR-125b (HR= 1.16; 95% CI: 0.71 to 1.89; P= 0.53) was not significant. Further, low miR-125 family expression was associated with clinicopathological features of liver metastasis (OR= 6.3; 95% CI: 1.1 to 36.3; P= 0.03). The sensitivity analysis shows that our results were completely powerful and stable. No potential publication bias was observed using Begg’s (P = 0.72) and Egger’s (P = 0.95) tests.
Conclusion: The low expression of miR-125 family predicts poor OS in GC patients. Thus, miR-125 family may be helpful as a potential biomarker for the prognosis of gastric cancer.